Certolizumab pegol

Frías, E. Delgado; González, Julia

doi:10.1016/j.reuma.2010.11.011

Cited by 7 publications

(3 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Elevated levels of TNF-α have been found in the targeted tissues of patients with different chronic inflammatory diseases. This finding, together with data on the clinical efficacy of pharmacological blockade of this cytokine, has confirmed the essential role of TNF-α in the pathogenesis of conditions such as RA, spondyloarthropathies, PsA, and Crohn’s disease 30. TNF-α plays a key role in the pathogenesis of Ps and PsA by inducing the production of other inflammatory cytokines such as interleukin (IL)-1, IL-6, IL-8, and several matrix metalloproteinases.…”

Section: Introductionsupporting

confidence: 58%

See 1 more Smart Citation

An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy

Acosta-Felquer

Rosa

Soriano

2016

OARRR

View full text Add to dashboard Cite

Certolizumab pegol (CZP) is a pegylated humanized tumor necrosis factor-α inhibitor (TNFi) approved for the treatment of psoriatic arthritis (PsA) in Europe, the USA, and Latin American countries. CZP neutralizes TNF-α at its soluble and membrane portions. Due to the lack of Fc region, it does not induce complement or antibody-dependent cytotoxicity in vitro, unlike other TNFi. RAPID-PsA study, the only randomized clinical trial performed in PsA, is a Phase III clinical trial conducted in 409 PsA patients during 24 weeks. Patients were randomized to CZP (200 mg every 2 weeks or 400 mg every 4 weeks) or placebo. Patients in CZP arms reported improvements in skin disease, joint involvement, dactylitis, enthesitis, and quality of life. Safety profile was similar to that reported for other TNF-α inhibitors in PsA patients. This article summarizes the pharmacology and reviews the efficacy and tolerability of this drug in PsA. CZP is the newest TNFi with proved efficacy in all manifestations of psoriasis disease, except for axial involvement where the evidence has been derived from response to axial spondyloarthritis.

show abstract

Section: Introductionsupporting

confidence: 58%

“…The lack of Fc region in CZP prevents activities such as complement fixation and antibody-mediated cytotoxicity. The attachment of the 40 kDa PEG moiety to the Fab fragment markedly increases the half-life of CZP to a value comparable with that of a whole antibody product 30,31…”

Section: Certolizumab Pegolmentioning

confidence: 99%

An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy

Acosta-Felquer

Rosa

Soriano

2016

OARRR

View full text Add to dashboard Cite

show abstract

“…The lack of the Fc region in CZP prevents activities such as complement fixation and antibody-mediated cytotoxicity. The attachment of the 40-kDa PEG moiety to the Fab fragment markedly increases the half-life of CZP to a value comparable with that of a whole antibody product [ 6 , 7 ]. CZP has been shown to improve patient-reported outcomes in rheumatoid arthritis (RA), PsA, and PsO [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

Certolizumab Pegol in the Treatment of Psoriasis and Psoriatic Arthritis: Preliminary Real-Life Data

Dattola

Cannizzaro

Mazzeo

et al. 2017

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

IntroductionWe present the results of real-life tests conducted in adults affected by psoriatic arthritis (PsA) with mild cutaneous involvement to evaluate the efficacy of certolizumab pegol (CZP), an anti-tumor necrosis factor-alpha agent approved in Europe for the treatment of rheumatoid arthritis and PsA.MethodsAssessments included an evaluation of the Psoriasis Area and Severity Index (PASI) and the Disease Activity Score computed on 44 joints (DAS-44) correlated to the erythrocyte sedimentation rate (ESR) (DAS44-ESR). A total of 41 patients (16 men, 25 women; mean age 59.8 ± 8 years) completed the study. Of these, 36 patients were affected by both PsA and psoriasis, and five patients were affected only by PsA. A total of 32 patients (group A) completed 3 months of treatment (W12), and 12 patients completed 6 months of treatment (W24) (group B).ResultsThe clinical efficacy of CZP was consistent on both the cutaneous and rheumatic components of the treatment. The mean PASI score decreased from 4.4 ± 4.7 at baseline (BL) to 2.3 ± 3.7 at W12 (group A), and from 5.1 ± 5.7 at BL to 0.8 ± 1.2 at W24 (group B). The DAS44-ESR decreased from 4.4 ± 0.6 at BL to a mean of 2.2 ± 0.9 at W12 (group A) and from 4.1 ± 0.6 at BL to a mean of 1.9 ± 0.5 at W24 (group B). No adverse events were reported.ConclusionOur results demonstrate that CZP can be used safely and effectively to treat both the cutaneous and joint components of PsA. However, long-term data are needed to confirm our preliminary observations.

show abstract

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics

Menter

Strober

Kaplan

et al. 2019

Journal of the American Academy of Dermatology

587

633

View full text Add to dashboard Cite

Certolizumab pegol

Cited by 7 publications

References 17 publications

An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy

An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy

Certolizumab Pegol in the Treatment of Psoriasis and Psoriatic Arthritis: Preliminary Real-Life Data

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics

Contact Info

Product

Resources

About